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Summary.-A tumour initiating dose of ethyl carbamate was administered to mice
by subcutaneous injection together with a dose of one of the homologous esters or an
ethyl N-alkyl derivative. The homologues used were the methyl, n-propyl and
n-butyl esters, and the derivatives were the N-methyl, N-ethyl and N-n-propyl ethyl
esters. The mice were then given promoting treatment with croton oil for 28 weeks.
Neither the homologous esters nor the N-substituted derivatives of ethyl carb-
amate had any influence on the yield of tumours in theskin, lung, or liver. However,
increasing the dose of ethyl carbamate increased the yields of tumours.
THE administration ofethyl carbamate
(urethane) to mice by any route leads to
the production of tumours in a variety of
tissues (Tannenbaum, 1964). Adenomata
of the lung (Nettleship et al., 1943;
Shimkin, 1955) are very common. Lym-
phomata with or without leukaemia
(Pietra et al., 1961), haemangiomata ofthe
liver (Trainin, 1963), and hepatomata are
less commonly found; tumours of lacri-
mal gland, skin and of other sites are
observed infrequently and only after a
long latent period. For skin its carcino-
genic action is mainly that of an initiator,
that is, tumours usually appear only when
the skin is subsequentlypaintedrepeatedly
with a promoting agent such as croton oil
(Graffi et al., 1953; Salaman and Roe,
1953; Berenblum and Haran, 1955).
The tumour initiating property of
carbamates for skin appears to be limited
to the ethyl ester and a few of its N-
substituted derivatives (Berenblum et al.,
1959b; Pound, 1967, 1969). The tumour
producing property for lung also appears
to be restricted to ethyl, ethyl N-methyl
and N-hydroxy carbamates although
propyl carbamate was considered to have
a doubtful effect (Larsen, 1947, 1948;
Berenblum et al., 1959b).
However, because of the common
chemical structure it might be thought
that the homologues, or the N-substituted
derivatives, of ethyl carbamate might
affect or be affected by similar metabolic
systems within the cells ofanimals injected
with them. Some related compounds
appear to produce similar abnormalities of
the chromosomes during mitosis in the
cells of animals, some eggs and plants
(Cornman, 1954; Boyland et al., 1965), and
lead to a similar depression of the white
cell counts in mice (Skipper et al., 1949).
The injection of homologues or deriva-
tives of ethyl carbamate at the same time
as the ethyl ester might therefore modify
the tumour producing properties of the
latter. Garcia (1963) reported that injec-
tion of butyl carbamate at the same time
as the ethyl ester reduced the number of
tumours initiated in the skin. The
experiments reported in this paper were
carried out to examine this proposition.
MATERIALS AND METHODS
Mice
Random bred male mice of the strain
" Hall " (Pound, 1962), about 7 weeks of age
and weighing 26 + 1 g at the beginning ofthe
experiments, were used. The animals were
divided into groups by random selection and
were housed in stainless steel compartmentsTUMOUR FORMATION IN MICE BY URETHANE
each containing 10 mice with a bed of coarse
sawdust that was changed weekly. The
animals were fed the standard diet used
previously and supplied with water ad
libitum. The mouse room was kept at a
temperature of 22°C. The hair on the skin
of the back was clipped with electric clippers
an hour or two before application of the
tumour promoting agents to the skin.
Chemicals
The chemicals used were as follows: ethyl
carbamate (British Drug Houses analytical
reagent); methyl, isopropyl, n-butyl, ethyl
N-methyl, ethylN-ethyl andethylN-n-propyl
carbamates (K. and K. Laboratories Inc.,
New York); n-propyl carbamate (Eastman
Organic Chemicals, Rochester, New York);
acetone (Anax analytical reagent). Croton
oil (A) used in Experiment I was a sample
from Stafford Allen and Sons, London, used
previously. Croton oil (B) used in Experi-
ments II and III was prepared by extraction
ofthe seed ofCroton tiglium (L) withmethanol
in an atmosphere of nitrogen.
The carbamates were administered in
0 75 ml of saline as an injection into the
subcutaneous tissue between the scapulae.
Solid carbamates were kept in solution by
warming when necessary. When the liquid
carbamates were not completely soluble 1%
serum (human) was included in the solution
and reasonably stable emulsions thenformed
on shaking.
Tumour initiating experiments
Groups of 40 mice were injected with
25 mg of urethane (0'432 LD50) and at the
same time with one of the homologues or an
additional amount of urethane. Two groups
of mice were injected with 25 mg of urethane
alone for each experiment, one before and the
other after the main series of injections.
Experiment I was commenced in April 1963;
Experiments II and III were commenced 3
years later and the mice were randomized
between these 2 experiments.
Thus the mice were injected with 0-432
LD50 urethane in the controls. This was
increased to 0-540, 0-650 and 0-864 LD50 by
the additional amount ofurethane in Experi-
ments I, II andIIIrespectively. Theoriginal
plan was to inject the other carbamates in
molecular equivalent amounts to the addi-
tional doses ofurethane, but these doses were
too lethal. The additional dose in each
experiment was therefore selected at an
arbitrary figure, standard for eachexperiment
as set out in the tables below.
In Experiment I the doses of the homo-
logues were as shown in Table II. From the
7th day after injection of the carbamates,
the mice were painted over the whole area of
the skin of the back with 0-25 ml of a 0.5%o
solution of croton oil (A) in acetone once each
week for 20 weeks. The time of appearance
of the first tumour was noted and the
numbers of tumours present recorded on
charts at the 14th and 22nd weeks. The
mice were then discarded without autopsy.
In Experiments II and III the additional
doses of urethane were 12-5 mg and 25 mg
respectively. The doses of homologues were
increased in Experiment II and again in
Experiment III as shown in Table III.
From the 7th day after injection of the
carbamates the mice were given an applica-
tion of 0-25 ml of a 0.075% solution of
croton oil (B) in acetone over the whole area
of the skin of the back once weekly for 28
weeks. The time of appearance of the first
tumour was noted and the number of
tumours present on the painted area were
recorded on charts at 12, 16, 20, 28, and 36
weeks. Animals that died before this time
were discarded without autopsy. After the
40th week obviously sick animals were killed
and with the remaining animals, which were
all killed at 50 weeks, subjected to autopsy.
A few animals died undetected early enough
to be suitable for autopsy. Skin lesions that
were considered to be malignant or doubtfully
malignant were confirmed by histological
examination, but it was not practical to
section all lesions. The number of mice with
lung adenomata and the number of lesions
were counted. Haemangiomata and hepa-
tomata in the liver were counted and the
diagnosisconfirmedhistologically. The num-
ber of mice with leukaemia was noted;
enlargement of the spleen and/or the thymus
was accepted as evidence ofleukaemia, but in
occasional cases blood smears or histological
sections were examined.
RESULTS
General Toxic and Narcotic Effects
The depth of narcosis produced by the
basal dose of ethyl carbamate was
increased, as expected, by the additional
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doses ofurethane or other carbamate, and
some animals died within 48 hours from
this cause. Table I sets out the dosage
schedules in the 3 experiments. The
basic dose of ethyl carbamate in each
experiment was 25 mg, i.e. 0*432 LD50.
The dosage of the additional carbamate
for each group is shown as a fraction ofits
LD50 as previously determined (Pound,
1967). The sums of the fractions of the
LD50 are also shown. The number of
survivors expected for the total fraction
of the LD50 does not differ significantly
from the number of survivors actually
found. The narcotic and toxic pro-
perties of the several carbamates are
therefore additive when the doses are
considered as fractions of the LD50.
Apart from the early deaths due to
narcosis, the death rates in the 3 experi-
ments and in all groups ofeach experiment
do not differ significantly.
Classification ofSkin Tumours
The skin tumours that arise after
initiation by urethane, followed by pro-
moting treatment with croton oil, behave
in a variety of ways that enable them to
be classified for the purpose of this paper
as benign papillomata, doubtfully malig-
nant lesions or carcinomata.
Benign papillomata
These constitute the majority of
growths. The lesions are first identified
when about 1 mm in diameter. A number
of lesions grow for a time and regress
during the treatment with croton oil, but
some continue to grow and may reach a
size ranging from 3 to 10 mm diameter.
Growth may continue even after cessation
of the croton oil treatment, and further
lesions may reach detectable size. As the
lesions age after cessation ofthe promoting
treatment a further proportion undergo
regression.
Histologically these lesions are typical
papillomata clothedbyhyperplastic strati-
fied squamous epithelium of regular char-
acter with a varying amount of keratin
formation, sometimes abundant. As the
lesions age they become less vascular and
form more keratin. Some finally atrophy
and disappear, but occasional lesions
become necrotic and are sloughed off.
Doubtfully malignant lesions
A proportion of the lesions commence
to grow in a similar manner to benign
papillomata but grow progressively and
may reach a considerable size, e.g. 12-15
mm in diameter. These lesions remain
vascular, become fleshy, and may differ
considerably in appearance from the
benign lesions. They may have a broad
pedicle or sit well into the dermis.
Histologically these lesions have a
papillary structure clothed by a deeply
staining active squamous epithelium with
many mitoses, and usually form much
keratin. The epithelium shows varying
degrees of invasion at the base, into the
dermis, or even into the underlying fat.
Lesions of this type rarely regress in
the period of observation. In this experi-
ment an occasional pedunculated lesion
sloughed off probably following mecha-
nical trauma during clipping. In one
instance in which this occurred, a squa-
mous cell carcinoma developed later at the
site. The impression has been formed
that a substantial proportion of these
lesions would become carcinoma if their
growth had been allowed to continue.
Carcinomata
A further proportion of the lesions
become frank carcinoma during the period
of observation. Histologically these vary
from moderately well differentiated squa-
mous cell carcinomata to anaplastic
spindle-celled growths, with invasion of
the deeper tissue, the muscularis panni-
culous carnosus, and even the body
musculature.
Tumour Yields
The number of mice with tumours of
the skin and the number of skin tumours
in each group at the 14th and 22nd week
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TABLE II.-Incidence ofSkin Tumours in Mice Injected with Urethane Together
with a Homologous Ester or an N-substituted Derivative Experiment I
Mice injected with
25 mg urethane
together with
Methyl carbamate .
n-Propyl carbamate
i-Propyl carbamate
n-Butyl carbamate.
Ethyl N-methyl carbamate
Ethyl N-ethyl carbamate
Ethyl N-n-propyl carbamate
Ethyl carbamate
mg
;-0
; 0
; 0
; 0
j 0
; 0
; 0
) *5
5
5
5
5
5
5
6
Surviving mice 14 weeks
Survivors, A_A
24 hours Number Mice Number
after of with of
injection mice tumours tumour
40 . 38 2 3
40 . 36 3 5
40 38 2 2
40 . 34 2 2
37 37 1 2
40 35 2 2
40 . 39 3 4
40 . 39 2 3
40 38 2 3
40 . 36 2 4
Surviving mice 22 weeks
Number Mice Number
of with of
mice tumours tumours
38 7 10 (2)
33 7 10 (1)
37 7 9
33 4
33 8 13 (2)
35 6 7
39 8 14 (1)
38 6 10 (1)
37 7 11 (1)
36 8 15 (2)
Figures in brackets are the numbers of the tumours that were malignant
of Experiment I are set out in Table II.
Similar parameters after the 12th, 20th
and 36th weeks ofExperiments II and III
are set out in Table III. Table IV sets
out the data from autopsy of animals that
died after the 40th week or were killed at
50 weeks. Skin tumours were classified as
above from the clinical behaviour in vivo,
or from sections of doubtful lesions taken
at autopsy.
Comparison ofthe tumour yields in the
skin of the control groups injected with
25 mg of urethane in Experiments I, II,
and III after approximately 20 weeks'
promoting treatment shows that the
number of mice with tumours, and the
total number of tumours in the surviving
mice, are approximately the same in
Experiments II and III but that the
yield of tumours is significantly greater in
these experiments than in Experiment I
(for the number of tumours per surviving
mice x2= 9-22, 2 d.f., P < 0.01). This is
probably due to a greater promoting
efficiency of the croton oil (B) used in
Experiments II and III which was
effective as a 0.075% solution in acetone
as compared with the 0-5% solution of
croton oil (A) used in Experiment I. In
both instances the concentrations were
about the maximum that could be used
without producing ulceration of the skin.
The results of Experiment I (Table II)
show no significant variation in survival
rate between the several groups (%2 = 2-5,
9 d.f., N.S.). Further, there is no signi-
ficant variation between the proportion of
surviving mice with tumours (x2 - 46,
9 d.f., N.S.) orthetotal number oftumours
in the surviving mice (%2 - 46, 9 d.f.,
N.S.) in the various groups. Even the
additionaldose ofurethanein Group 10 did
not produce a statistically significant
increase in the tumour yield.
The results of Experiments II and III
(Tables III and IV) may be considered
together since the results show no signi-
ficant variation in the tumour yields in
the control groups injected with 25 mg of
urethane. Apart from the early deaths
due to toxic effects ofthe carbamates, the
death rates do not differ in the 2 experi-
ments.
Ifthe Groups 9 in Experiments II and
III are excluded, there is no significant
variation in the number of mice with skin
tumours or in the number of tumours in
the surviving mice at 12, 20, 36, and 50
weeks after the administration of the
urethane. There is no significantvariation
in these groups in the proportion of sur-
viving mice with adenomata in the lungs,
nor in the number of adenomata. The
number of tumours in the liver, haeman-
giomata and hepatomata, and the number
of mice with leukaemia do not vary
significantly between the groups.
On the other hand, the number of
tumours in the surviving mice is signi-
ficantly greater in Group 9 of each
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experiment, which received the additional
dose of urethane (Experiment II, x2 9-4
1 d.f., P < 0 005 at 36th week; Experi-
ment III, x2 49 1 d.f., P < 0-001 at
36th week). Further, the tumour yield is
greater in the mice in Group 9 of Experi-
ment III, which had a dose of 50 mg of
urethane, than in Group 9 of Experiment
II which had 37'5 mg. The increased
tumour yields in Group 9 of Experiments
II and III are significant at the 12th, 20th,
36th, and 50th weeks.
The proportion of the surviving mice
with lung tumours and the number of
lung adenomata are also increased in
Groups 9 of Experiments II and III. The
number of lung adenomata is significantly
greater in Group 9 ofExperiment III than
in Group 9 ofExperiment II, in conformity
with the larger dose of urethane.
The number of liver tumours and the
number of mice with leukaemia do not
vary significantly in any group but the
numbers are too small to allow any valid
conclusion.
It is evident that the number of
tumours increases steadily from the time
ofappearance ofthe first tumours at about
the 8th week for about 36 weeks and
thereafter declines. Since the applications
of croton oil were discontinued after 28
weeks, tumours must continue to develop
for a time after cessation of the promoting
treatment before the number regressing
becomes greater than the number of new
ones appearing. In these experiments
many tumours eventually regressed. On
the other hand, the number of malignant
tumours increased steadily from the time
they were first recognized.
DISCUSSION
It is relevant to the present issue that,
when a given dose ofurethane was injected
together with graded doses of one or other
of its homologues or N-substituted deriva-
tives, the narcotic potencies of the com-
bined injections were such as to be
expected if the toxicity of the compounds
is additive in accordance with Ferguson's
rule (Ferguson, 1939).
16§
When the mice were given a fixed
tumour initiating dose ofethyl carbamate,
the simultaneous injection of one of the
homologous methyl, propyl, and ethyl
carbamates, or of the related ethyl
N-methyl, N-ethyl, or N-propyl carb-
amates, did not produce any significant
change in the tumour yield in any tissue.
The proportion of mice that developed
skin tumours and the total number ofskin
tumours in the surviving mice was
unaltered at any stage after promoting
treatment was commenced, that is, the
rate ofproduction oftumours and the rate
ofregression was unaltered and, moreover,
the number ofmalignant tumours was also
unchanged.
On the other hand, an increase in the
dose of ethyl carbamate increased the
number of lung tumours, the number of
tumours in the liver, and perhaps the
incidence of leukaemia. It produced an
increase in the yield of skin tumours at all
times after promoting treatment was
commenced, and in the proportion of skin
tumours that were malignant. A similar
increased yield of tumours with increasing
dose ofurethane has been found by others
(Berenblum and Haran-Ghera, 1957; Roe
and Salaman, 1954).
The failure of the homologous alkyl
carbamates to increase the tumour yield
is consistent with previous work, sug-
gesting that these compounds have very
little, ifany, potency as tumour producing
agents in mice for skin and lung (Larsen,
1947, 1948; Berenblum et al., 1959b;
Pound, 1967 and unpublished data). The
fact that they, as well as the N-substituted
derivatives of ethyl carbamate, had no
effect on the tumour yield substantiates
the view that the biochemical events
resulting in the production of tumours by
urethane are not related to those cellular
processes that result in narcosis. This
view was formerly based on observations
that the tumour producing properties and
the narcotic properties of carbamates
depend on different chemical features of
the molecule (Berenblum et al., 1959b;
Pound, 1967, 1969), and that the adminis-
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tration of lysergic acid diethylamide
(LSD-25) at the same time as urethane
obviates the narcosis but does not in-
fluence the tumour yields (Berenblum et
al., 1959a).
Ethyl-N-methyl carbamate, however,
is more than half as potent as ethyl
carbamate, while ethyl-N-ethyl and ethyl-
N-propyl carbamates are progressively
less active in their tumour initiating
property for mouse skin and tumour
producing property in mouse lung (Beren-
blum et al., 1959b; Pound, 1967 and
unpublished data). The higher doses of
ethyl-N-methyl carbamatewouldprobably
be effective if given alone and perhaps
should be expected to lead to increased
tumour yields when given together with
ethyl carbamate if the tumour producing
effects were simply additive in the same
way as an addition to the dose ofurethane,
particularly since they are chemically
closely related and probably act through
the same metabolic pathways. Neverthe-
less, no significant increase in tumour
yields was found. Perhaps further infor-
mation on this point might be obtained.
However, the carcinogenic potency of
carbamates appears to be fairly specific to
the ethyl esters with not more than one
hydrogen substituted on the amide nitro-
gen (Pound, 1967, 1969), suggesting the
existence of a specific metabolic pathway
to an active intermediate. The present
result suggests that the unsubstituted
ethyl carbamate is metabolized to the
active carcinogen in preference to the N-
substituted compounds when both are
present in an animal.
Garcia (1963) reported that the admin-
istration of butyl carbamate at the same
time as the ethyl ester reduced the number
of skin tumours obtained after subsequent
promoting treatment with croton oil. The
discrepancy with the present results may
be related to the fact that he administered
the compounds as a series of small
injections, over a period which appears to
have been about 23 days in one group,
although the actual dosage schedules were
not set out. These conditions are likely to
induce the formation of enzymes that
metabolize the compounds, as is known to
occur in the case of ethyl carbamate
(Conney, 1965) and the dicarbamate
meprobamate (Phillips et al., 1962), so
that less is available for carcinogenic
action. A report that the administration
ofethyl carbamate as a course ofinjections
over several days resulted in the initiation
of fewer tumours than if it had been given
as a single large dose (Berenblum and
Haran-Ghera, 1957) possibly reflects a
similar phenomenon.
This work was supported by grants
from the Queensland Cancer Fund and the
Mayne Bequest Fund of the University of
Queensland.
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